Your session is about to expire
← Back to Search
Flortaucipir Imaging for Lewy Body Disease
Study Summary
This trial is looking at how quickly people with Dementia with Lewy bodies (DLB) decline and what affects this decline.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have another neurological disorder, like multiple sclerosis or a brain tumor, that could affect the study results.If having a Tau imaging test, you cannot have a prolonged QT interval on your heart's electrical activity.You have been diagnosed with probable dementia with Lewy bodies.You are not unable to have an MRI scan.
- Group 1: Dementia with Lewy Bodies
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are any new applicants currently being considered for this clinical trial?
"The data hosted on clinicaltrials.gov displays that this trial is no longer accepting patients, as it was first posted in the 25th of June 2018 and last updated on December 1st 2022. Nevertheless, 121 other trials are presently open for recruitment."
How many participants can take part in this experiment?
"Unfortunately, recruitment for this study is currently suspended. First posted on June 25th 2018 and last modified December 1st 2022, those hoping to participate need to seek alternative studies at the moment. Currently, 116 trials are enrolling patients with Lewy Body Disease while 5 separate studies require 18F-Flortaucipir participants."
Could you detail other investigations involving 18F-Flortaucipir?
"18F-Flortaucipir was initially investigated in 2008 at the Mayo Clinic. Since then, 7 trials have been successfully conducted and 5 more are currently underway across many locations based primarily around Rochester, Minnesota."
To what extent can 18F-Flortaucipir prove detrimental to individuals?
"With Phase 4 trial results backing it, 18F-Flortaucipir has earned a safety ranking of 3 on the Power scale."
Share this study with friends
Copy Link
Messenger